OncoSec - IMMUNOPULSE® IL-12

Manufactured by  OncoSec
Follow this Equipment

To date, OncoSec’s immunotherapy platform, ImmunoPulse®, focuses on the delivery of DNA-based interleukin-12 (IL-12), a...

To date, OncoSec’s immunotherapy platform, ImmunoPulse®, focuses on the delivery of DNA-based interleukin-12 (IL-12), a naturally occurring protein with immune-stimulating functions. The treatment is designed to produce a controlled, localized expression of IL-12 in the tumor microenvironment, which in turn, enables the immune system to target and attack tumors throughout the body. 
 
OncoSec is currently investigating ImmunoPulse® IL-12 for treatment of metastatic melanoma and triple negative breast cancer. As the company continues to evaluate ImmunoPulse® IL-12 in these current indications, OncoSec is developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches.
Active Questions & AnswersAsk a Question

There are no current Discussions

DNA Sequencing Reagents Service ProvidersView All (3)

Request Support
Documents & Manuals

There are no Documents or Manuals available.

Features

There are no Features available.

General Specifications

There are no General Specifications available.

Looking for New or Used Equipment?

Shop on LabX

Shop on Labx.com